Course Content
Module 1: Basic ECMO
Module I: Extracorporeal Membrane Oxygenation Basics (ECMO Basics) This module covers the foundational knowledge of ECMO, including circuit physiology, components, and basic ECMO management. Duration: 3 Weeks (Course weeks 1 to 3) Week 1: Introduction to ECMO Week 2: ECMO Physiology & Circuit Management Week 3: ECMO Complications and Troubleshooting Module I Pretest: 30 MCQs
0/20
Module II: Veno-venous Extracorporeal Membrane Oxygenation (VV ECMO)
This module focuses on the use of VV ECMO in patients with respiratory failure. Topics include ARDS management, VV ECMO cannulation strategies, and VV ECMO troubleshooting. Duration: 3 Weeks (Course weeks 4 to 6) Module II Pretest: 30 MCQs Week 4: VV ECMO Fundamentals Start Date: July 20, 2025 a. Respiratory failure and ARDS management (Ahmed Magdey) b. Evidence for VV ECMO use and landmark trials (Hesham Faisal) c. VV ECMO cannulation techniques and pros and cons of different VV ECMO configuration choices (Moustafa Esam) d. ECMO Retrieval and Patient Transport on ECMO (Ahmed Labib)
0/22
Module III: Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)
This module focuses on VA ECMO for cardiogenic shock, including cannulation strategies, LV unloading, and advanced applications. Duration: 3 Weeks (Course weeks 7 to 9) Module II Pretest: 30 MCQs
0/19
Extra Corporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS) course (Copy 4)

ARDS in HIV Patients and VV ECMO Considerations (Mohamed Hussein Ahmed)

HIV Patients on ECMO Bridge

Mohamed Hussein presented a case series of three HIV patients treated with ECMO at the Manchester ECMO Center, highlighting that ECMO can be successfully used as a bridge to recovery in selected patients with type 1 respiratory failure. The patients were young, newly diagnosed with HIV, and had no significant comorbidities. The ECMO duration was prolonged, averaging about a month, and patients experienced prolonged ICU and hospital stays. Hussein emphasized the importance of careful patient selection and discussed the challenges and complications associated with managing HIV patients on ECMO.

ECMO Treatment and Patient Outcomes

Hussein presented two ECMO cases, describing the treatment protocols and challenges faced. The first patient, a male with necrotizing pneumococcal pneumonia, was treated with antiretroviral therapy, steroids, IVIG, and Acyclovir for HSV-1, while battling complications including Aki, multi-organ failure, and invasive pulmonary aspergillosis. The second patient, a 28-year-old female with newly diagnosed HIV and severe ARDS, was successfully cannulated and retrieved on VV-ECMO, requiring tracheostomy and prolonged ICU and hospital stays. Both patients showed significant improvement in imaging and clinical outcomes.

ECMO Cases in HIV Patients

Hussein presented two cases of ECMO patients with HIV and Pneumocystis jiroveci pneumonia (PJP). The first patient required two rounds of ECMO, antiretroviral therapy, and second-line treatment for PJP, while the second patient was admitted twice with respiratory failure, initially managed with ECMO and antiretroviral therapy. Both patients faced challenges including absorption issues, co-infections, and complications such as DVT and intracerebral bleed, but showed significant improvement in their lung condition after treatment.

HIV Patient ECMO Case Study

Hussein presented a case study of a patient with HIV who required ECMO support for a month due to severe respiratory failure. The patient experienced multiple complications including CMV infection, gastrointestinal bleeding, and deep vein thrombosis, but showed significant improvement on imaging after ECMO weaning. Hussein emphasized the importance of multidisciplinary team meetings in ECMO care and highlighted key learning points for managing HIV patients on ECMO, including the need for careful cannulation, prolonged ECMO duration, and close monitoring for bleeding and thrombosis risks.

HIV Management and Treatment Strategies

Hussein presented on HIV infection management, recommending early involvement of specialists and high-dose septrin alongside steroids. He highlighted a high incidence of viral co-infections and secondary infections, advocating for early antiretroviral treatment within the first week despite the risk of immune reconstitution inflammatory syndrome. Hussein also discussed complications like gut failure and specific conditions like Kaposi’s sarcoma, noting that antiretroviral treatment alone was effective without chemotherapy, and addressed HLH with bulse steroids and IVIG.

Saving Lives Academy
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.